Department of Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Eur J Haematol. 2013 Oct;91(4):332-8. doi: 10.1111/ejh.12171. Epub 2013 Aug 17.
Cytogenetic studies of patients with diffuse large B-cell lymphoma (DLBCL) have revealed a large spectrum of chromosomal abnormalities, some of which may be clinically relevant. We wanted to evaluate possible associations between commonly acquired chromosome aberrations and prognosis in a large cohort of patients.
All patients with DLBCL treated at our center during 1999-2010 with an abnormal G-banding karyotype determined on cells short-term cultured from diagnostic biopsies were included. Detailed information on staging, treatment, and outcome was available for all patients.
Of the 110 patients available for analysis, there were 48 deaths and 27 relapses after a median follow-up of 4.5 yr. Eleven different chromosomal abnormalities were detected in more than ten percent of patients. Of those, only loss of 17p, including the TP53 tumor suppressor gene, was significantly associated with inferior long-term prognosis. Five year overall and progression-free survival frequencies were 32% and 27% for patients with loss of 17p and 67% and 59% in patients without this abnormality.
In a relatively large cohort of patients with DLBCL analyzed by chromosome banding, loss of 17p was the only chromosomal abnormality associated with inferior survival in uni- and multivariate analysis.
对弥漫性大 B 细胞淋巴瘤（DLBCL）患者的细胞遗传学研究揭示了一系列广泛的染色体异常，其中一些可能与临床相关。我们希望在一个大型患者队列中评估常见获得性染色体异常与预后之间的可能关联。
纳入了 1999 年至 2010 年期间在我们中心接受治疗的所有通过短期培养诊断性活检细胞确定存在异常 G 带核型的 DLBCL 患者。所有患者的分期、治疗和结果的详细信息均可用。
在可进行分析的 110 例患者中，有 48 例死亡，27 例在中位随访 4.5 年后复发。在超过 10%的患者中检测到 11 种不同的染色体异常。其中，只有 17p 缺失（包括 TP53 肿瘤抑制基因）与较差的长期预后显著相关。缺失 17p 的患者 5 年总生存率和无进展生存率分别为 32%和 27%，而无此异常的患者分别为 67%和 59%。
在通过染色体带分析的相对较大的 DLBCL 患者队列中，缺失 17p 是单变量和多变量分析中唯一与生存不良相关的染色体异常。
